Association of serum MMP-9 with autoantibodies against oxidized LDL.

[1]  T. Shoji,et al.  Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[2]  Sillanaukee,et al.  Association of serum sialic acid and MMP‐9 with lipids and inflammatory markers , 2000, European journal of clinical investigation.

[3]  M. Emoto,et al.  Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. , 2000, Atherosclerosis.

[4]  M. Uusitupa,et al.  Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[5]  G. Reaven,et al.  PPARgamma agonists enhance human vascular endothelial adhesiveness by increasing ICAM-1 expression. , 1999, Biochemical and biophysical research communications.

[6]  S. Kaul,et al.  Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. , 1999, Circulation.

[7]  T. Lehtimäki,et al.  Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[8]  S. George.  Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. , 1998, Current opinion in lipidology.

[9]  O. Wiklund,et al.  Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[10]  M. Davies.  Reactive oxygen species, metalloproteinases, and plaque stability. , 1998, Circulation.

[11]  L. Berglund,et al.  Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[12]  W. Frishman,et al.  Matrix Metalloproteinases and Coronary Artery Disease: A Novel Therapeutic Target , 1997, Journal of clinical pharmacology.

[13]  J. Nilsson,et al.  Human Monocytes/Macrophages Release TNF-α in Response to Ox-LDL , 1996 .

[14]  T. Nikkari,et al.  Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. , 1996, The American journal of pathology.

[15]  G. Nuovo,et al.  Elevated levels of 92-kd type IV collagenase (matrix metalloproteinase 9) in giant cell arteritis. , 1996, Arthritis and rheumatism.

[16]  L. Niskanen,et al.  Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[17]  E. Falk,et al.  Pathophysiology and inflammatory aspects of plaque rupture. , 1996, Cardiology clinics.

[18]  J. Boer,et al.  Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. , 1996, Atherosclerosis.

[19]  T. Matsumura,et al.  Lysophosphatidylcholine potentiates the mitogenic activity of modified LDL for human monocyte-derived macrophages. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[20]  V. Fuster,et al.  Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. , 1995, Circulation.

[21]  W. Klein,et al.  Transient reduction of autoantibodies against oxidized LDL in patients with acute myocardial infarction. , 1995, Free radical biology & medicine.

[22]  J. Isner,et al.  Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. , 1995, Circulation.

[23]  E. Miller,et al.  Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Halliwell,et al.  Metal ion release from mechanically-disrupted human arterial wall. Implications for the development of atherosclerosis. , 1995, Free radical research.

[25]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[26]  Y. Soini,et al.  72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[27]  W. Klein,et al.  Autoantibodies to oxidized low density lipoproteins in restenosis following coronary angioplasty. , 1994, Cardiology.

[28]  D. Steinberg,et al.  Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[29]  G. Finardi,et al.  Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. , 1993, Coronary artery disease.

[30]  J L Witztum,et al.  Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Kornitzer,et al.  The World Health Organization MONICA Project (Monitoring trends and determinants in cardiovascular disease): A major international Collaboration , 1988 .

[32]  D. Steinberg,et al.  Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. , 1987, Proceedings of the National Academy of Sciences of the United States of America.